A heart-rate-reducing medication reduces the risk of heart failure and cardiac fibrosis

The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure (left ventricular insufficiency) and cardiac fibrosis.

Read the whole article on Physorg

More from Physorg